Fosfomycin Tromethamine | CAS#78964-85-9

MedKoo Cat#: 317954 | Name: Fosfomycin Tromethamine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fosfomycin trometamine is an antibiotic produced by Streptomyces fradiae.

Chemical Structure

Fosfomycin Tromethamine

CAS#78964-85-9 (Tromethamine)

Theoretical Analysis

MedKoo Cat#: 317954

Name: Fosfomycin Tromethamine

CAS#: 78964-85-9 (Tromethamine)

Chemical Formula: C7H18NO7P

Exact Mass: 0.0000

Molecular Weight: 259.19

Elemental Analysis: C, 32.44; H, 7.00; N, 5.40; O, 43.21; P, 11.95

Price and Availability

Size	Price	Availability
250mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 800.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

23155-02-4 (free acid) 26016-98-8 (calcium) 26469-67-0 (calcium hydrate) 26016-99-9 (sodium) 78964-85-9 (Tromethamine)

Synonym

Fosfomycin Tromethamine; Fosfomycin tromethanol; Tromethamine-fosfomycin; Fosfomycin trometamol salt; Fosfomycin tromethamine [USAN]; Tromethamine, Fosfomycin; Phosphomycin; Phosphonomycin;

IUPAC/Chemical Name

2-amino-2-(hydroxymethyl)propane-1,3-diol; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid(1:1)

InChi Key

QZJIMDIBFFHQDW-LMLSDSMGSA-N

InChi Code

InChI=1S/C4H11NO3.C3H7O4P/c5-4(1-6,2-7)3-8;1-2-3(7-2)8(4,5)6/h6-8H,1-3,5H2;2-3H,1H3,(H2,4,5,6)/t;2-,3+/m.0/s1

SMILES Code

C[C@H]1[C@H](O1)P(=O)(O)O.C(C(CO)(CO)N)O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 259.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A, Larrosa N, Almirante B. Fosfomycin-tromethamine long-term oral therapy for difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother. 2015 Dec 14. pii: AAC.02611-15. [Epub ahead of print] PubMed PMID: 26666924. 2: Khawaja AR, Khan FB, Dar TI, Bhat AH, Wani MS, Wazir BS. Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study. Cent European J Urol. 2015;68(3):371-5. doi: 10.5173/ceju.2015.590. Epub 2015 Oct 15. PubMed PMID: 26568884; PubMed Central PMCID: PMC4643705. 3: Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. J Coll Physicians Surg Pak. 2014 Dec;24(12):914-7. doi: 12.2014/JCPSP.914917. PubMed PMID: 25523727. 4: Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi BK, Yang WM, Zhao XK, Gao XF, Chen M. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013 Dec 4;3(12):e004157. doi: 10.1136/bmjopen-2013-004157. PubMed PMID: 24309172; PubMed Central PMCID: PMC3855495. 5: Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3. PubMed PMID: 23742831. 6: Knottnerus BJ, Nys S, Ter Riet G, Donker G, Geerlings SE, Stobberingh E. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother. 2008 Aug;62(2):356-9. doi: 10.1093/jac/dkn177. Epub 2008 Apr 19. PubMed PMID: 18424789. 7: Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):153-60. PubMed PMID: 18336741. 8: Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G; Italian Medici Medicina Generale (MMG) Group. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy. 2005 May;51(2-3):162-6. Epub 2005 May 9. PubMed PMID: 15886477. 9: Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999 Jan;43(1):137-40. PubMed PMID: 10381112. 10: Barry AL, Pfaller MA, Fuchs PC, Tenover FC, Reller LB, Allen SD, Hardy DJ, Gerlach EH. Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):352-6. PubMed PMID: 8354302. 11: Cilli F, Pullukcu H, Aydemir S, Sipahi OR, Tasbakan M, Turhan A, Ulusoy S. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents. 2008 Mar;31(3):297-8. doi: 10.1016/j.ijantimicag.2007.11.003. Epub 2008 Jan 3. PubMed PMID: 18180144. 12: Aykut Arca E, Karabiber N. [Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics]. Mikrobiyol Bul. 2007 Jan;41(1):115-9. Turkish. PubMed PMID: 17427560. 13: Tempera G, Mirabile M, Mangiafico A, Caccamo M, Bonfiglio G. Fosfomycin tromethamine in uncomplicated urinary tract infections: an epidemiological survey. J Chemother. 2004 Apr;16(2):216-7. PubMed PMID: 15216960. 14: Stein GE. Fosfomycin tromethamine: single-dose treatment of acute cystitis. Int J Fertil Womens Med. 1999 Mar-Apr;44(2):104-9. Review. PubMed PMID: 10338268. 15: Stein GE. Single-dose treatment of acute cystitis with fosfomycin tromethamine. Ann Pharmacother. 1998 Feb;32(2):215-9. Review. PubMed PMID: 9496408. 16: Fuchs PC, Barry AL, Brown SD. Susceptibility testing quality control studies with fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis. 1997 Jul;16(7):538-40. PubMed PMID: 9272392. 17: Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997 Apr;53(4):637-56. Review. PubMed PMID: 9098664. 18: Pfaller MA, Barry AL, Fuchs PC. Evaluation of disk susceptibility testing of fosfomycin tromethamine. Diagn Microbiol Infect Dis. 1993 Jul;17(1):67-70. PubMed PMID: 8359009. 19: Barry AL, Fuchs PC. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother. 1991 Jun;35(6):1235-8. PubMed PMID: 1929270; PubMed Central PMCID: PMC284319.